SK31999A3 - Use of sibutramine analogues to prevent the development of diabetes - Google Patents

Use of sibutramine analogues to prevent the development of diabetes Download PDF

Info

Publication number
SK31999A3
SK31999A3 SK319-99A SK31999A SK31999A3 SK 31999 A3 SK31999 A3 SK 31999A3 SK 31999 A SK31999 A SK 31999A SK 31999 A3 SK31999 A3 SK 31999A3
Authority
SK
Slovakia
Prior art keywords
insulin
formula
compound
medicament
manufacture
Prior art date
Application number
SK319-99A
Other languages
English (en)
Slovak (sk)
Inventor
Clifford J Bailey
Robert B Jones
Helen C Jackson
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of SK31999A3 publication Critical patent/SK31999A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrotherapy Devices (AREA)
SK319-99A 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes SK31999A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process
PCT/EP1997/005039 WO1998011884A1 (fr) 1996-09-21 1997-09-15 Utilisation d'analogues de sibutramine pour empecher l'evolution du diabete

Publications (1)

Publication Number Publication Date
SK31999A3 true SK31999A3 (en) 1999-12-10

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
SK319-99A SK31999A3 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Country Status (26)

Country Link
US (3) US6174925B1 (fr)
EP (1) EP0927028A1 (fr)
JP (1) JP2001503737A (fr)
KR (1) KR20000048501A (fr)
CN (1) CN1237905A (fr)
AU (1) AU724488B2 (fr)
BG (1) BG64473B1 (fr)
BR (1) BR9711517A (fr)
CA (1) CA2266401C (fr)
CZ (1) CZ93699A3 (fr)
GB (1) GB9619757D0 (fr)
HR (1) HRP970505A2 (fr)
HU (1) HUP9904026A3 (fr)
ID (1) ID18320A (fr)
IL (1) IL128850A (fr)
MY (1) MY116150A (fr)
NO (1) NO991358L (fr)
NZ (1) NZ334580A (fr)
PL (1) PL332305A1 (fr)
RU (1) RU2245709C2 (fr)
SK (1) SK31999A3 (fr)
TR (1) TR199900618T2 (fr)
TW (1) TW580385B (fr)
UA (1) UA64726C2 (fr)
WO (1) WO1998011884A1 (fr)
ZA (1) ZA978450B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
WO2000000195A1 (fr) * 1998-06-30 2000-01-06 Takeda Chemical Industries, Ltd. Composition pharmaceutique pour le traitement du diabete
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
CA2351058A1 (fr) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Composition pharmaceutique a liberation modifiee d'un agent de sensibilisation a l'insuline, et d'un autre agent antidiabetique
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
EP1185232A1 (fr) 1999-06-01 2002-03-13 University Of Texas Southwestern Medical Center Methode de traitement de la perte des cheveux a l'aide de composes de sulfonyle thyromimetiques
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (fr) * 2001-04-13 2002-10-24 Sepracor Inc. Procedes permettant la preparation de didesmethylsibutramine et d'autres derives de sibutramine
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
WO2004030663A1 (fr) * 2002-10-05 2004-04-15 Hanmi Pharm. Co., Ltd. Composition pharmaceutique comprenant de l'hemihydrate de methanesulfonate de sibutramine cristallin
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
TW200517127A (en) * 2003-08-07 2005-06-01 Sb Pharmco Inc Novel composition
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
DK1677792T3 (en) * 2003-10-31 2015-12-14 Takeda Pharmaceutical FIXED COMPOSITION INCLUDING PIOGLITAZONE, GLIME PIRIDE AND A POLYOXYETHYLENE-SORBITAN Fatty Acid Ester.
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
WO2007081857A2 (fr) 2006-01-06 2007-07-19 Sepracor Inc. Cycloalkylamines inhibiteurs du recaptage des monoamines
MX2009002781A (es) 2006-09-15 2009-03-30 Reviva Pharmaceuticals Inc Sintesis, metodos de uso y composiciones de cicloalquilmetilaminas .
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
JP2010510306A (ja) * 2006-11-22 2010-04-02 エスケー ケミカルズ カンパニー リミテッド シブトラミンとベータ−シクロデキストリンの包接複合体
CA2939778C (fr) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Peptides p53 stabilises et utilisations de ceux-ci
BRPI0809366B8 (pt) 2007-03-28 2021-05-25 Harvard College polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
WO2012003501A2 (fr) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthèse et procédés d'utilisation de dérivés de cycloalkylméthylamine
CN103282510A (zh) 2010-08-13 2013-09-04 爱勒让治疗公司 拟肽大环化合物
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
ES2726807T3 (es) 2011-12-30 2019-10-09 Reviva Pharmaceuticals Inc Composiciones, síntesis y métodos de uso de derivados de 1-[1-fenil-ciclobutil]isobutilamina
EP2822572B1 (fr) 2012-02-15 2020-06-10 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
CA2961258A1 (fr) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Macrocycles peptidomimetiques et leurs utilisations
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (fr) 1993-10-14 1995-04-20 Biomedica California, Inc. Traitement et prophylaxie du diabete
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
US6617360B1 (en) 2003-09-09
RU2245709C2 (ru) 2005-02-10
TR199900618T2 (xx) 1999-06-21
JP2001503737A (ja) 2001-03-21
TW580385B (en) 2004-03-21
IL128850A (en) 2003-07-31
MY116150A (en) 2003-11-28
UA64726C2 (uk) 2004-03-15
CZ93699A3 (cs) 1999-08-11
IL128850A0 (en) 2000-01-31
US20040077730A1 (en) 2004-04-22
NO991358D0 (no) 1999-03-19
HRP970505A2 (en) 1998-08-31
BR9711517A (pt) 1999-08-24
WO1998011884A1 (fr) 1998-03-26
CN1237905A (zh) 1999-12-08
AU724488B2 (en) 2000-09-21
CA2266401A1 (fr) 1998-03-26
US6174925B1 (en) 2001-01-16
NZ334580A (en) 2000-09-29
KR20000048501A (ko) 2000-07-25
PL332305A1 (en) 1999-08-30
NO991358L (no) 1999-03-19
GB9619757D0 (en) 1996-11-06
CA2266401C (fr) 2007-01-30
ID18320A (id) 1998-03-26
HUP9904026A2 (hu) 2000-05-28
ZA978450B (en) 1999-03-19
AU4774097A (en) 1998-04-14
HUP9904026A3 (en) 2000-07-28
BG64473B1 (bg) 2005-04-30
EP0927028A1 (fr) 1999-07-07
BG103277A (en) 2000-01-31

Similar Documents

Publication Publication Date Title
US6174925B1 (en) Use of sibutramine analogues to prevent the development of diabetes
US6187820B1 (en) Medical treatment to improve lipid levels
US6365633B1 (en) Method of treating eating disorders
WO2001062341A2 (fr) Agents therapeutiques
EP1007023B1 (fr) Derives de 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine pour l'abaissement du taux d'acide urique chez l'homme
BG104568A (bg) Фармацевтичен състав, съдържащ сибутрамин и орлистат
US6376552B1 (en) Treatment of gallstones
US6372798B1 (en) Treatment of hyperactivity disorders
US6372797B1 (en) Treatment of menstrual function
US6441046B1 (en) Control of metabolism
US6403650B1 (en) Treatment of pulmonary hypertension
MXPA99002598A (en) Use of sibutramine analogues to prevent the development of diabetes
US6288125B1 (en) Treatment of hiatial hernia
US6433020B1 (en) Treatment of cardiovascular disease
MXPA00006201A (en) Pharmaceutical composition containing sibutramine and orlistat
MXPA99002633A (en) Use of sibutramine analogues to lower lipid levels